Treosulfan and gemcitabine [1] (multiple letters)

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 5, 2005, Pages 329-330

  Cree, Ian A ^a   Neale, Michael H ^b   Reinhold, Uwe ^c   Kurbacher, Christian M ^c   Terheyden, P ^d   Brocker E B ^d   Becker, J C ^d  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

^c Praxis Clin for Dermato Oncol Bonn   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CISPLATIN; GEMCITABINE; TREOSULFAN; ANTINEOPLASTIC AGENT; BUSULFAN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; HUMAN; LETTER; PRIORITY JOURNAL; MELANOMA; NOTE; REPRODUCIBILITY; UVEA TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DEOXYCYTIDINE; HUMANS; MELANOMA; REPRODUCIBILITY OF RESULTS; UVEAL NEOPLASMS;

EID: 17644414953     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0630-3     Document Type: Letter

References (11)

1. 1. Cree 2003 Rec Res Cancer Res 161 119 Cree IA (2003) Chemosensitivity testing as an aid to anti-cancer drug and regimen development. Rec Res Cancer Res 161:119–125
2. 2. Grecu 2001 ASCO Proceedings 20 187b Grecu OM, Kurbacher CM, Mallmann P, Bruckner HW, Cree IA (2001) Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO clinical study group. ASCO Proceedings 20:187b
3. 3. Hartley 1999 Br J Cancer 79 264 Hartley JA, O’Hare CC, Baumgart J (1999) DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer 79:264–266
4. 4. Kurbacher 2003 Rec Res Cancer Res 161 221 Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, Konecny G, Bruckner HW, Cree IA (2003) ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Rec Res Cancer Res 161:221–230
5. 5. Myatt 1997 Anticancer Drugs 8 756 Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1997) The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 8:756–762
6. 6. Neale 1999 Br J Cancer 79 1487 10.1038/sj.bjc.6690237 1:CAS:528:DyaK1MXitFGrsro%3D 10188895 Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1999) Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 79:1487–1493
7. 7. Neale MH (2001) Ph.D Thesis, University of London
8. 8. Peters GJ, Ruiz van Haperen VW, Bergmann AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ (1996) Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23[Suppl 10]:16–14
9. 9. Pfohler 2003 Anticancer Drugs 14 337 10.1097/00001813-200306000-00002 12782938 Pfohler C, Cree IA, Ugural S, Kuwert C, Haass N, Neuber K, Hengge U, Corrie PG, Zutt M, Tilgen W, Reinhold U (2003) Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicentre feasibility study. Anticancer Drugs 14:337–340
10. 10. Sharma 2003 BMC Cancer 3 19 Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19
11. 11. Terheyden 2004 J Cancer Res Clin Oncol 130 395 Terheyden P, Brocker EB, Becker JC (2004) Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol 130:395–399